ArticleScientific reports2019
Lipophilic statins inhibit Zika virus production in Vero cells.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- CD151 identifies a cytotoxic CD4 T cell population enriched in people with HIV that later develop cancer.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Fatty acid transporter protein isoform 2 (FATP2) inhibitor lipofermata inhibits Zika virus replication and blocks fatty acid uptake in SH-SY5Y neuroblastoma cell line.Microbiology spectrum · 2026Article
- Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence.Cancer innovation · 2026Review
- Zika virus and host protein interactions for understanding molecular mechanisms of pathogenesis and therapeutic development.Frontiers in cellular and infection microbiology · 2026Review
- Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens.Nature communications · 2025Article
- Do Statins Affect Viral Infections Encountered by International Travelers?Tropical medicine and infectious disease · 2025Review
- The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection.Virology journal · 2024Review
- Cryogenic electron microscopy and tomography reveal imperfect icosahedral symmetry in alphaviruses.PNAS nexus · 2024Article
- Zika virus prM protein contains cholesterol binding motifs required for virus entry and assembly.Nature communications · 2023Article
- The La Crosse virus class II fusion glycoproteinJournal of virology · 2023Article
- Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.Viruses · 2023Article
- The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Zika virus triggers autophagy to exploit host lipid metabolism and drive viral replication.Cell communication and signaling : CCS · 2023Article
- Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.International journal of molecular sciences · 2023Article
- Effects of Statin Combinations on Zika Virus Infection in Vero Cells.Pharmaceutics · 2022Article
- Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis.Scientific reports · 2022Article
- Pathophysiological Role of Vimentin Intermediate Filaments in Lung Diseases.Frontiers in cell and developmental biology · 2022Review
- Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2Frontiers in microbiology · 2022Article
- Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19.Frontiers in nutrition · 2022Review
- Metabolic syndrome and aberrant immune responses to viral infection and vaccination: Insights from small animal models.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family. ZIKV infection has been associated with neurological complications such as microcephaly in newborns and Guillain-Barré syndrome in adults; thus, therapeutic agents are urgently needed. Statins are clinically approved for lowering cholesterol levels to prevent cardiovascular disease but have shown potential as antiviral drugs. In this study, we explored the possibility of utilizing statins as anti-ZIKV drugs. We found that, generally, lipophilic statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, and simvastatin) could reduce ZIKV production in vitro and result in smaller foci of infection. Time-of-drug-addition assay revealed that early treatment with statins is more beneficial than late treatment; however, statins could not completely inhibit the entry stage of ZIKV infection. Furthermore, individual lipophilic statins differed in anti-ZIKV capacity, with fluvastatin being the most efficient at low concentrations. Taken together, this study shows that statins or their derivatives have the potential to be used as anti-ZIKV therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.